Researchers at University of Tsukuba have demonstrated that during Japan's COVID-19 booster vaccination campaign, online information influenced vaccination intentions in ways similar to the initial ...

Valneva's Phase 2 data show strong, lasting immunity for its Pfizer-partnered Lyme vaccine as the company consolidates operations in France.

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15. The results showed ...

Whooping cough, a bacterial infection that can be especially dangerous for babies and young children, is on the rise. As of ...

Real-world effectiveness with the recommended single dose of respiratory syncytial virus (RSV) vaccination dipped in older ...

A joint procurement contract between the EU and Danish manufacturer Bavarian Nordic strengthens vaccine preparedness against ...

The FDA’s top vaccine regulator asserted in a staff email that the Covid vaccine caused at least 10 kids' deaths, but experts ...

Investing.com -- Valneva SE stock rises after the company reported final positive Phase II data for its Lyme disease vaccine candidate VLA15, showing strong immune responses following a third annual ...

More than a year after its promised deadline to investors, drugmaker puts alarming results in federal government's "virtual ...

Through the episode, the trio highlights the advantages of using in-house tests, how rapid titer testing enables personalized ...

New details from health officials suggest the whooping cough surge may be part of a national pattern driven by slipping ...

Today’s announcement is a powerful example of what our Vaccine Alliance does best,” said An Vermeersch, Gavi’s Chief Vaccine ...